RESEARCH PLAN ? RUTGERS CANCER INSTITUTE OF NEW JERSEY OVERALL PROJECT SUMMARY/ABSTRACT The Rutgers Cancer Institute of New Jersey (CINJ) is a matrix/consortium (with Princeton University) and New Jersey?s only NCI-designated Comprehensive Cancer Center, serving a diverse population of 8.9 million people. CINJ focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). The rapid trajectory of CINJ?s growth validated the initial vision that one of the Nation?s largest public universities of the health sciences would rapidly bring forth an NCI-designated Cancer Center. CINJ has 227 members (206 Rutgers, 19 Princeton, and 2 collaborating). The State Cancer Registry and Surveillance, Epidemiology, and End Results (SEER) Program was moved to CINJ in 2011, and as a result of state legislation in 2013, CINJ became an independent institute of Rutgers University, optimizing CINJ?s potential for growth, transdisciplinary collaboration, and impact across the catchment area. In FY2018, CINJ received over $68 million in support from Rutgers and Princeton, the State, the Health System, and philanthropy. Direct peer-reviewed support increased ~16%. Members published 3,664 cancer focused publications since 2011 (20% inter- and 24% intra-programmatic, 55% inter-institutional). In January 2017, Steven K. Libutti was appointed Director of CINJ and Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences (RBHS). In a strategic partnership with the RWJBarnabas Health System, Libutti was named Senior Vice President for Oncology Services. CINJ is now positioned to coordinate both cancer research and care throughout its catchment area. An iterative strategic planning process resulted in reorganization of research Programs to increase collaborations, cancer focus, translation, and investigator-initiated clinical trials. These five Programs are: 1) Cancer Metabolism and Growth (CMG), 2) Genomic Instability and Cancer Genetics (GICG), 3) Cancer Pharmacology (CP), 4) Clinical Investigations and Precision Therapeutics (CIPT), and 5) Cancer Prevention and Control (CPC). These Programs are supported by eight shared resources (Biomedical Informatics, Biometrics, Biorepository and Histopathology Services, Comprehensive Genomics, Flow Cytometry/Cell Sorting, Genome Editing, Metabolomics, and Research Pharmacy), with two developing shared resources (Immune Monitoring, Small Molecule Screening). The Statewide authority of CINJ derives from its status as the only NCI-designated Cancer Center; extensive and direct support by the State of New Jersey to serve as the State?s oncology resource; opportunities to conduct translational and population research within the most diverse and densely populated State in the nation; and the synergistic opportunities for collaboration across outstanding research institutions. This supports CINJ?s mission to reduce the burden of cancer in its catchment by advancing cancer research, prevention, screening and education.
RUTGERS CANCER INSTITUTE OF NEW JERSEY PUBLIC HEALTH RELEVANCE STATEMENT New Jersey has a population of approximately 8.9 million with a yearly cancer incidence of 50,000 new cases and a yearly mortality of 16,500 deaths. Rutgers Cancer Institute of New Jersey (CINJ) is the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center. The mission of CINJ is to reduce the burden of cancer by advancing cancer research, prevention, screening and education for one of the nation?s most diverse and densely populated states as well as for the broader nation.
|Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182|
|Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459|
|Laval, K; Vernejoul, J B; Van Cleemput, J et al. (2018) Virulent Pseudorabies Virus Infection Induces a Specific and Lethal Systemic Inflammatory Response in Mice. J Virol 92:|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Lalani, Almin I; Zhu, Sining; Xie, Ping (2018) Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay. J Vis Exp :|
|Warner, Wayne A; Lee, Tammy Y; Badal, Kimberly et al. (2018) Cancer incidence and mortality rates and trends in Trinidad and Tobago. BMC Cancer 18:712|
|Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468|
|Farber, Nicholas J; Radadia, Kushan D; Singer, Eric A (2018) Accuracy of Nodal Staging and Outcomes of Lymphadenectomy for Non-metastatic Renal Cell Carcinoma: An Analysis of the National Cancer Database. Bladder Cancer 4:S14-S15|
|Poillet-Perez, Laura; Xie, Xiaoqi; Zhan, Le et al. (2018) Autophagy maintains tumour growth through circulating arginine. Nature 563:569-573|
|Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158|
Showing the most recent 10 out of 775 publications